Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster lunch

1872 - Micro-RNA down express ABCG2 gene in Adjuvant Chemotherapy in Female Breast Cancer (561P)


18 Nov 2017


Poster lunch


Samen Saeed


Annals of Oncology (2017) 28 (suppl_10): x173-x176. 10.1093/annonc/mdx679


S. Saeed1, M.N. Faisal1, W. Majeed1, J. Hussain1, H. Muzaffar1, A. Mahmood2, H. Javed1

Author affiliations

  • 1 Institute Of Pharmacy,physiology And Pharmacology, University of agriculture, Faisalabad, 38040 - Faisalabad/PK
  • 2 Institute Of Pharmacy, Physiology & Pharmacology, University of Agriculture, Faisalabad, 38040 - Faisalabad/PK


Abstract 1872


Cancer is a group of the devastating disease having worldwide distribution, characterized by persistent proliferation or regeneration of cells. Breast cancer is a type of cancer that involves breast tissue and is one of the leading causes of deaths in women.


The current study was designed to determine the expression level of BCRP encoded by ABCG2 gene has a central role in the pharmacokinetics of both xenobiotic and drugs as well as contributes to multidrug resistance in cancer therapy. Quantitative real-time PCR was used to determine the gene expression level and analysis.


The expression level of micro-RNA in up regulation of breast cancer resistance gene was determined as well as Foxo is playing a key role. Results showed that the relative Mir 140, Mir 145 and Micro 328 genes expression level are significantly higher expression level in breast cancer patient which down-regulate the ABCG protein. Src and mTOR genes are highly expressed in breast cancer patient. The data was analyzed statistically by using ANOVA and DMR test for significance.


Results concluded that higher expression of microRNA, mTor and FOXO down regulate the ABCG2 gene and stimulate the process of chemo-resistance, cell proliferation, apoptosis resistance.

Clinical trial identification

Legal entity responsible for the study

Ethical Review Committee, Punjab Medical College, Faisalabad.




All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.